Relatlimab

1 Drug classified under this active ingredient

IgG4 Monoclonal Antibody. Nivolumab 12 mg/ml, Relatlimab 4 mg/ml.
12 mg nivolumab+ 4 mg relatlimab/ml
Conc. for sol. for IV,1 X 20 ml
 480 mg nivolumab and 160 mg relatlimab every 4 weeks as IV over 30 min. For  adlts. and ped. pts 12 years and older weighing at least 30 kg
Tmt. of adlt and ped. pts. 12 years or older with unresect. or metast. melanoma
C/I:Hypersens